Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Shanghai Duyiwei Biotech Strikes mAb Deal with Apexigen

publication date: Mar 6, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Shanghai Duyiwei Biotechnology, a subsidiary of Gansu Duyiwei Biological Pharma, announced an agreement with California-based Apexigen to develop monoclonal antibody drugs to treat cancer. Shanghai Duyiwei is paying $13.8 million to help underwrite Apexigen’s drug development costs. Apexigen previously established collaborations with Simcere Pharma and 3SBio. More details....

Stock Symbols: (SHE: 002219) (NYSE: SCR) (NSDQ: SSRX)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors